Pharmaceutical Manufacturing

Pharmaceutical manufacturing is under unprecedented scrutiny following nitrosamine recalls, the GLP-1 shortage and compounding controversy, and the geopolitical re-shoring push under the CHIPS-and-Science-era industrial policy. WCPD 2027 will cover continuous manufacturing adoption (Janssen, Vertex, Eli Lilly), Quality-by-Design implementation under ICH Q12, and PAT-driven release. Sessions will also address mRNA and LNP manufacturing scale-up post-pandemic, viral vector capacity constraints, generics quality and the FDA's GDUFA III commitments, drug shortage prevention under the CARES Act reporting requirements, and the emerging role of distributed and point-of-care manufacturing for personalized cell therapies.